Nine in 10 consumers unaware what counterfeit medicines are: survey | Healthcare Asia Magazine
, Hong Kong

Nine in 10 consumers unaware what counterfeit medicines are: survey

More than half of respondents believe that it is the same as generic medicine.

Almost nine in 10 consumers or 88% of Hong Kong consumers are unaware or do not have a clear understanding of what counterfeit medicines are, a survey on consumer attitudes by healthcare services company Zuellig Pharma revealed.

Counterfeit medicine refers to fake medicine, according to the Food and Drug Administration. It may be contaminated or contain the wrong or no active ingredient; or may have the right active ingredient but at the wrong dose. Zuellig Pharma noted that counterfeit medicine may include branded or generic medication whereby the identity or the source has been deliberately and fraudulently mislabeled, and may include products with wrong ingredients, insufficient or without active ingredients, or with fake packaging.

More than half or 52% of respondents incorrectly believe that counterfeit medicines are the same as generic medicines, showing low levels of understanding, the survey noted.

This is despite 61% of respondents saying that they seek advice from healthcare professionals before purchasing medicine, and despite checking three to four sources before purchasing medication.

Further, whilst 91% of respondents place importance on verifying their medicine, 58% expressed a lack of confidence in how to do so. In fact, 57% were found unlikely to verify the authenticity of the medication they buy.

“The research shows an urgent need to raise the public’s understanding on counterfeit medicines and provide them with ways to protect themselves. Globally, counterfeit medicines are on the rise and kill one million people a year, or hinder treatment progress.6 It is everyone’s responsibility to take precautionary measures to fight against counterfeiters,” said Andi Umbricht, chief executive, Hong Kong and Macau, Zuellig Pharma. 

Pemindaian AI terkini meningkatkan diagnosa di Shin Kong Wu Ho-Su Memorial Hospital

Rumah sakit di Taiwan ini menggunakan teknologi endoskop yang dibantu AI untuk mendeteksi polip dan kamera resolusi tinggi untuk telemedis.

Kejeniusan dalam ‘SuperApps’ untuk perawatan kesehatan adalah akses dan jangkauan

Rumah sakit yang merangkul digitalisasi tetap unggul dalam layanan kesehatan.

Rumah Sakit Kanker Dharmais memimpin inovasi pelayanan kanker di Indonesia

Direktur Utama RS Kanker Dharmais Soeko Werdi Nindito Daroekoesoemo mengungkapkan teknologi canggih dan tujuh program unggulan untuk perawatan kanker.

Healthway Cancer Care Hospital memajukan perawatan holistik dengan harga yang wajar

Rumah sakit mengharapkan program kualitas dan kelangsungan hidup yang melayani keseluruhan perjalanan pasien.

MakatiMed menuju perawatan bedah presisi dengan sistem robotik Da Vinci Xi

Teknologi ini memungkinkan teknik invasif minimal dalam bidang urologi, hepatobilier, kardiovaskular, toraks, kebidanan dan ginekologi, serta bedah umum.

Indonesia memperluas dukungan solusi kesehatan menggunakan AI

Kolaborasi dengan Google Cloud sejalan dengan cetak biru pemerintah untuk transformasi kesehatan digital.

Indonesia merancang rencana induk untuk pengembangan kesehatan terpadu

Rencana induk sektor kesehatan negara (RIBK) selaras dengan mandat Undang-Undang Kesehatan Nomor 17 Tahun 2023.

The Medical City membuka jalan bagi integrasi AI dalam layanan kesehatan lokal dan penelitian dengan Lunit

AI telah diintegrasikan ke dalam layanan mamografi dan rontgen dada di jaringan rumah sakit ini.

Mayapada Healthcare Group meraih prestasi besar di Healthcare Asia Awards 2024

Pendekatan holistik yang dilakukan oleh rumah sakit tersebut mendorongnya maju dan menjadi standar industri.

Rumah Sakit Kanker Dharmais meraih dua kemenangan di Healthcare Asia Awards 2024

Sumber daya manusia yang kompeten, layanan, fasilitas, dan infrastruktur unggul membantu rumah sakit memberikan perawatan pasien yang sangat baik.